Department of Psychiatry, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.
Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria.
Metab Brain Dis. 2021 Mar;36(3):509-521. doi: 10.1007/s11011-020-00656-6. Epub 2021 Jan 7.
Current diagnoses of mood disorders are not cross validated. The aim of the current paper is to explain how machine learning techniques can be used to a) construct a model which ensembles risk/resilience (R/R), adverse outcome pathways (AOPs), staging, and the phenome of mood disorders, and b) disclose new classes based on these feature sets. This study was conducted using data of 67 healthy controls and 105 mood disordered patients. The R/R ratio, assessed as a combination of the paraoxonase 1 (PON1) gene, PON1 enzymatic activity, and early life time trauma (ELT), predicted the high-density lipoprotein cholesterol - paraoxonase 1 complex (HDL-PON1), reactive oxygen and nitrogen species (RONS), nitro-oxidative stress toxicity (NOSTOX), staging (number of depression and hypomanic episodes and suicidal attempts), and phenome (the Hamilton Depression and Anxiety scores and the Clinical Global Impression; current suicidal ideation; quality of life and disability measurements) scores. Partial Least Squares pathway analysis showed that 44.2% of the variance in the phenome was explained by ELT, RONS/NOSTOX, and staging scores. Cluster analysis conducted on all those feature sets discovered two distinct patient clusters, namely 69.5% of the patients were allocated to a class with high R/R, RONS/NOSTOX, staging, and phenome scores, and 30.5% to a class with increased staging and phenome scores. This classification cut across the bipolar (BP1/BP2) and major depression disorder classification and was more distinctive than the latter classifications. We constructed a nomothetic network model which reunited all features of mood disorders into a mechanistically transdiagnostic model.
目前的情绪障碍诊断并未进行交叉验证。本文旨在解释如何使用机器学习技术:(a) 构建一个模型,该模型集成了风险/韧性 (R/R)、不良结局途径 (AOPs)、分期和情绪障碍表型;(b) 根据这些特征集揭示新的类别。本研究使用了 67 名健康对照者和 105 名情绪障碍患者的数据。R/R 比值作为对氧磷酶 1 (PON1) 基因、PON1 酶活性和早期生活时间创伤 (ELT) 的组合进行评估,可预测高密度脂蛋白胆固醇-对氧磷酶 1 复合物 (HDL-PON1)、活性氧和氮物种 (RONS)、硝氧化应激毒性 (NOSTOX)、分期 (抑郁和轻躁狂发作次数和自杀企图次数) 和表型 (汉密尔顿抑郁和焦虑评分以及临床总体印象;当前自杀意念;生活质量和残疾测量) 评分。偏最小二乘路径分析显示,表型的 44.2%方差由 ELT、RONS/NOSTOX 和分期评分解释。对所有特征集进行的聚类分析发现了两个不同的患者聚类,即 69.5%的患者被分配到一个具有高 R/R、RONS/NOSTOX、分期和表型评分的类别,30.5%的患者被分配到一个具有增加的分期和表型评分的类别。这种分类跨越了双相情感障碍 (BP1/BP2) 和重性抑郁障碍的分类,比后者的分类更具特色。我们构建了一个分类网络模型,将情绪障碍的所有特征整合到一个具有机制跨诊断的模型中。